ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy

Abstract summary

Demonstrated that APOE4 impairs microglial amyloid clearance and exacerbates tau-mediated neurodegeneration. Anti-APOE antibodies reduced amyloid plaque burden in mouse models. APOE4 microglia show impaired phagocytic capacity relative to APOE3 microglia, directly linking APOE genotype to microglial function.

Evidence labels

Therapeutic relevance

Anti-APOE antibody approach validated in preclinical models, supporting ongoing interest in APOE-targeted therapies.